Work

Real-world use of pembrolizumab in Germany: patient characteristics and survival

Year: 2025

Type: conference-paper

Abstract: Background: Pembrolizumab was the drug that incurred the highest costs for statutory health insurance in Germany in 2023. Using real-world data, we aimed to characterize patients treated with pembrolizumab in Germany and describe their overall survival. Materials and Methods: Using claims data, we [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/25gaa17

Authors: Scholle, Oliver, Kollhorst, Bianca, Heinig, Miriam, Haug, Ulrike

Institution: Leibniz Institute for Prevention Research and Epidemiology - BIPS

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7104997108

FWCI:

Cites:

Cited by:

Related to: